An experimental therapeutic cancer vaccine induced two distinct and desirable immune system responses that led to significant tumor regression in mice.This is according to a new research study published in the journal Cell, reported by investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).According to the research findings, intravenous (IV) administration of the vaccine boosted the number of cytotoxic T cells capable of infiltrating and attacking tumor cells and engaged the innate immune system by inducing type I interferon.SNAPvax, the name of the experimental vaccine, was designed by Robert Seder, M.D., and colleagues at the NIAID Vaccine Research Center (VRC) together with collaborators from Vaccitech North America, a clinical-stage biopharmaceutical company in Baltimore, Maryland.This substance, it was also determined, had significant anti-viral/cancer capabilities, protected the Glans from bacterial assault and, much like the prepuce of the Clitoris, maintained the sensitivity of said “structure”; AKA The Glans Penis."